Copyright 2024 All rights reserved.

Development of Extracellular

Vesicle Therapies that are safe for

everyone without any immune rejection

STEMMEDICARE has been steadily researching and developing

innovative therapeutics to cure various intractable diseases through

immune-tolerized cells and their extracellular vesicles.

Development of Extracellular

Vesicle Therapies that are safe for

everyone without any immune rejection

STEMMEDICARE has been steadily researching and developing

innovative therapeutics to cure various intractable diseases through

immune-tolerized cells and their extracellular vesicles.

Development of Extracellular

Vesicle Therapies that are safe for

everyone without any immune rejection

STEMMEDICARE has been steadily researching and developing

innovative therapeutics to cure various intractable diseases through

immune-tolerized cells and their extracellular vesicles.

R&D Pipeline

  • Atopic
    Dermatitis     Restoration of skin barrier function and instant itching relief efficacy by inducing non-autoreactive regulatory T cells
  • Osteoartiritis Non-surgical therapeutics with anti-inflammation and hyaline cartilage regeneration efficacy
    (designed for DMOAD)
  • Anti-Cancer Innovative anti-cancer therapeutics targeting abnormal Tumor Microenvironment inhibiting normal immune activities
  • Neurodegerative
    Diseases     EV therapeutics that pass through Blood-Brain-Barrier and normalize autophagic function to degrade abnormal reactive proteins
  • Infectious
    Diseases     Newly discovered IgP-containing EV therapeutics applicable to prevention and treatment of all infectious diseases, including COVID-19

What we do

  • Retro-Genesis
    Therapy
  • Overcoming
    Immune Rejection
  • Extracellular Vesicle (EV)
    Therapeutics
  • Primal Immune
    System

Core technology

Development of
Immune-tolerized
Cells & Evs

STEMMEDICARE has developed all core technologies for the entire process of manufacturing cell lines and extracellular vesicles without immune rejection, based on immune tolerance mechanism during pregnancy in which a fetus is fully protected from the attack of mother’s immune system.

World’s First
FBS & DMSO-free
Cryopreservation Agents

STEMMEDICARE has developed world’s first cryopreservation agent containing immune-tolerized EVs replacing FBS and DMSO, which cause animal protein-derived immune responses, various side effects, and DNA alteration.

Platform Technology
for mass production & isolation
of HLA-G+ immune-tolerized EVs

STEMMEDICARE has established innovative PLAFORM technology for inducing immune-tolerized cell lines regardless of cell origin and manufacturing HLA-G+ EV therapeutics with higher purity and concentration.

LOCATION

If you visit our company,
Please refer to the LOCATION page.

Inquiry

If you have any questions,
please use the online inquiry form.